CASI To Build GMP Mfg. Site In Wuxi, China

CASI Pharmaceuticals has entered into agreements to build a state-of-the-art manufacturing site in the Wuxi Huishan Economic Development Zone in Jiangsu Province, China. The Wuxi Huishan Economic Development Zone is a science and technology innovation center in the region.
 
The facility will be designed and constructed based on global cGMP requirements and is expected to have capacity for large-scale production. The facility will be a key asset supporting CASI’s growth and commercialization plans with further agreements to be finalized and site construction to begin in mid-2019.
 
“We are excited about moving forward with building our own manufacturing site as part of our supply chain,” said Wei-Wu He, executive chairman, CASI. “The facility will be a core component of our long-term growth strategy as it will give us significantly greater capacity in order to meet the company’s commercial needs, and also will allow us greater control over quality, cost of goods and to accelerate production schedules.”